This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical: Archive
New Strong Buy Stocks for May 6th
by Zacks Equity Research
INTT, EOG, UVE, LQDA and UMBF have been added to the Zacks Rank #1 (Strong Buy) List on May 6, 2026.
EOGPositive Net Change INTTNegative Net Change UMBFPositive Net Change UVEPositive Net Change LQDAPositive Net Change
computers finance insurance medical oil-energy
Do Options Traders Know Something About Cardinal Health Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to CAH stock based on the movements in the options market lately.
CAHPositive Net Change
medical
ENSG Tops Q1 EPS Estimates on Patient Growth, Raises '26 Outlook
by Zacks Equity Research
Ensign Group tops Q1 EPS estimates as occupancy gains and acquisitions fuel growth, while higher costs and a slight revenue miss temper results.
UNHNegative Net Change HCANegative Net Change ENSGNegative Net Change ELVNegative Net Change
earnings medical
Pediatrix Medical Q1 Earnings Beat Estimates on Same-Unit Strength
by Zacks Equity Research
Pediatrix Medical Group tops Q1 estimates as stronger reimbursements and same-unit gains lift results despite lower patient volumes.
MDNegative Net Change HCANegative Net Change ENSGNegative Net Change ELVNegative Net Change
earnings medical
IQV Q1 Earnings Beat on Commercial Solutions Strength
by Zacks Equity Research
IQVIA tops on Q1 EPS and revenues on strong Commercial Solutions growth, lifts its 2026 EPS outlook and keeps the revenue & EBITDA guidance steady.
ADPNegative Net Change VRSKNegative Net Change IQVPositive Net Change
medical
BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance Raised
by Zacks Equity Research
BMRN misses Q1 EPS estimates despite a revenue beat, as charges and higher costs weigh on profits, while new Amicus deal lifts the 2026 outlook.
SNYNegative Net Change BMRNNegative Net Change CPRXPositive Net Change CSTLNegative Net Change
biotechs earnings gene-therapy medical pharmaceuticals
Viatris Gears Up to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
VTRS gears up to report Q1 results as import alerts, regional pressures and growth in key brands shape expectations ahead of May 7 release.
NVOPositive Net Change AGENPositive Net Change INOPositive Net Change VTRSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Inspire Medical Q1 Earnings Beat Estimates, 2026 View Cut, Stock Down
by Zacks Equity Research
INSP beats Q1 estimates but slashes 2026 outlook as reimbursement disruptions and WISeR program weigh on growth and procedure volumes.
ISRGNegative Net Change CAHPositive Net Change WSTPositive Net Change INSPNegative Net Change
earnings medical medical-devices
Are Options Traders Betting on a Big Move in Agenus Stock?
by Zacks Equity Research
Investors need to pay close attention to AGEN stock based on the movements in the options market lately.
AGENPositive Net Change
medical
Do Options Traders Know Something About Amneal Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to AMRX stock based on the movements in the options market lately.
AMRXPositive Net Change
medical